novo glp-1 drug Ro Launches Wegovy® Pill Through Integration with Nordisk Novo, Lilly weight-loss drugs should

many, however, stringently captured HF events as secondary endpoints

While most major insurers and Medicare plans cover GLP-1s for T2D, coverage for GLP-1s for obesity and weight management is much more limited and often excluded from standard plans

This work was further supported by German Research Foundation Grants DFG-TS226/1-1, DFG-TS226/3-1, and DFG-TR152 (project no

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N

10.1007/s00125-018-4729-5 72

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials